Upgrade to SI Premium - Free Trial

Acadia Pharmaceuticals (ACAD) PT Lowered to $39 at Mizuho, 'Daybue Seasonality Trend May Raise Concerns'

February 28, 2024 6:15 AM
Mizuho Securities analyst Uy Ear lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $39.00 (from $40.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles